The U.S. Food and Drug Administration has accepted a New Drug Application from Teva Pharmaceuticals and Medincell for TEV-'749, an investigational once-monthly subcutaneous olanzapine formulation designed to treat schizophrenia in adults. The submission marks a significant advancement in long-acting antipsychotic therapy, as the candidate treatment aims to provide monthly dosing while maintaining the efficacy profile of existing olanzapine formulations.
Data from the Phase 3 SOLARIS clinical trial demonstrated that TEV-'749 met efficacy and safety endpoints consistent with currently available olanzapine treatments. A key differentiation of the investigational formulation is the elimination of post-injection monitoring requirements, which are mandatory with certain existing long-acting injectable antipsychotics. This feature addresses a practical clinical consideration that impacts patient convenience and healthcare resource allocation.
The FDA's acceptance of the NDA allows the regulatory agency to conduct a formal review of the application. The approval would represent an additional option within the long-acting injectable antipsychotic class, which aims to improve treatment adherence and clinical outcomes for adult patients managing schizophrenia.